| IgG Fc engineering to modulate antibody effector functions X Wang, M Mathieu, RJ Brezski Protein & cell 9 (1), 63-73, 2018 | 422 | 2018 |
| Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice M Lo, HS Kim, RK Tong, TW Bainbridge, JM Vernes, Y Zhang, YL Lin, ... Journal of Biological Chemistry 292 (9), 3900-3908, 2017 | 295 | 2017 |
| Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling JE Stadanlick, M Kaileh, FG Karnell, JL Scholz, JP Miller, WJ Quinn Iii, ... Nature immunology 9 (12), 1379-1387, 2008 | 259 | 2008 |
| A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor–resistant lung tumors SL Moores, ML Chiu, BS Bushey, K Chevalier, L Luistro, K Dorn, ... Cancer research 76 (13), 3942-3953, 2016 | 252 | 2016 |
| Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages Y Shi, X Fan, H Deng, RJ Brezski, M Rycyzyn, RE Jordan, WR Strohl, ... The Journal of Immunology 194 (9), 4379-4386, 2015 | 225 | 2015 |
| An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations O Vafa, GL Gilliland, RJ Brezski, B Strake, T Wilkinson, ER Lacy, ... Methods 65 (1), 114-126, 2014 | 212 | 2014 |
| Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? RJ Brezski, RE Jordan MAbs 2 (3), 212-220, 2010 | 180 | 2010 |
| Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function KD Grugan, FL McCabe, M Kinder, AR Greenplate, BC Harman, JE Ekert, ... The Journal of Immunology 189 (11), 5457-5466, 2012 | 135 | 2012 |
| Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease P Biancheri, RJ Brezski, A Di Sabatino, AR Greenplate, KL Soring, ... Gastroenterology 149 (6), 1564-1574. e3, 2015 | 132 | 2015 |
| Immunoglobulin isotype knowledge and application to Fc engineering RJ Brezski, G Georgiou Current opinion in immunology 40, 62-69, 2016 | 108 | 2016 |
| Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge RJ Brezski, O Vafa, D Petrone, SH Tam, G Powers, MH Ryan, JL Luongo, ... Proceedings of the National Academy of Sciences 106 (42), 17864-17869, 2009 | 106 | 2009 |
| Membrane Cholesterol Content Accounts for Developmental Differences inSurface B Cell Receptor Compartmentalization andSignaling FG Karnell, RJ Brezski, LB King, MA Silverman, JG Monroe Journal of Biological Chemistry 280 (27), 25621-25628, 2005 | 85 | 2005 |
| A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy X Fan, RJ Brezski, M Fa, H Deng, A Oberholtzer, A Gonzalez, ... Breast Cancer Research 14, 1-13, 2012 | 72 | 2012 |
| Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1 TC Nesspor, TS Raju, CN Chin, O Vafa, RJ Brezski Journal of Molecular Recognition 25 (3), 147-154, 2012 | 66 | 2012 |
| B-cell receptor RJ Brezski, JG Monroe Multichain Immune Recognition Receptor Signaling: From Spatiotemporal …, 2008 | 62 | 2008 |
| Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs RJ Brezski, JL Luongo, D Petrone, MH Ryan, D Zhong, SH Tam, ... The Journal of Immunology 181 (5), 3183-3192, 2008 | 58 | 2008 |
| Engineered protease-resistant antibodies with selectable cell-killing functions M Kinder, AR Greenplate, KD Grugan, KL Soring, KA Heeringa, ... Journal of Biological Chemistry 288 (43), 30843-30854, 2013 | 54 | 2013 |
| The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge RJ Brezski, A Oberholtzer, B Strake, RE Jordan MAbs 3 (6), 558-567, 2011 | 51 | 2011 |
| An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions M Kinder, AR Greenplate, WR Strohl, RE Jordan, RJ Brezski MAbs 7 (3), 494-504, 2015 | 49 | 2015 |
| Humanized anti-CD134 (OX40) antibodies and uses thereof PJ Simons, L Boon, J Luo, R Brezski, M Goldberg US Patent 9,790,281, 2017 | 45 | 2017 |